Today: 23 May 2026
BP Stock Soars as Oil Rally and Strategic Shift Boost Investor Confidence
18 November 2025
2 mins read

BP plc (LON: BP.) Today—Share Price Softens as Brent Slips; Olympic Pipeline Partially Restored (18 November 2025)

LONDON — 18 November 2025. BP shares eased in morning trade in London as oil prices dipped back toward $63–$64 a barrel, while the company said it had restarted an unaffected segment of the Olympic Pipeline in Washington state after a weekend leak. The operational update helped limit concerns about refined‑product flows in the U.S. Pacific Northwest, but the softer crude backdrop kept pressure on the stock.

BP share price today (LSE: BP.)

By late morning, BP traded at 458.70p, down about 1.1% on the day. The intraday range stood around 456.95p–460.85p versus a previous close of 463.60p. FT data time‑stamped 10:42 GMT put the group’s market value near £72.2bn.

Operations: Olympic Pipeline update

BP said it had partially restored the Olympic Pipeline system east of Everett, Washington, after a refined‑products release led to a shutdown of lines in the area on Sunday. The unaffected segment resumed deliveries on Sunday, while the incident remains under investigation. Importantly, Seattle‑Tacoma International Airport reported no impact to operations and adequate jet‑fuel storage. Olympic is a roughly 400‑mile network carrying gasoline, diesel and jet fuel from northern Washington to Oregon.

Oil market backdrop

Crude was softer on Tuesday as Russia’s Novorossiysk export hub resumed loadings following a brief halt linked to a drone and missile strike. At about 07:20 GMT, Brent was down 0.9% to $63.64 per barrel and WTI slipped to $59.37. The resumption at Novorossiysk—together with traders re‑assessing the impact of Western sanctions on Russian flows—tempered supply worries that had lifted prices late last week. For BP, day‑to‑day moves in Brent typically filter into sentiment for the London‑listed integrated major.

Capital returns and near‑term calendar

BP’s buyback and dividend framework remain the key supports for the equity story this quarter. Alongside its third‑quarter results earlier this month, BP said it intends to execute a $0.75 billion share buyback before reporting fourth‑quarter results, reinforcing guidance to return 30–40% of operating cash flow to shareholders over time (including dividends and buybacks). The Q3 dividend was announced at 8.320 cents per ordinary share.

On timing, FT market data shows BP’s ex‑dividend date was 13 November 2025, with a payment date of 19 December 2025—useful reference points for income‑focused holders tracking near‑term cash distributions.

What to watch next

  • Pipeline resolution: Further detail on the Olympic Pipeline investigation and full restoration would reduce operational uncertainty in a region that depends on the line for gasoline, diesel and jet fuel.
  • Crude price path: With Brent hovering in the low‑$60s and global supply headlines in flux, BP’s share direction is likely to mirror broader moves in energy markets in the near term.
  • Buyback execution: Confirmation of the Q4 buyback progress, plus any end‑year guidance tweaks, will shape expectations into the 2026 outlook.

Bottom line: On 18 November 2025, BP is trading modestly lower as oil prices ease, while the company’s partial restart of the Olympic Pipeline helps contain U.S. refined‑product disruption risk. With a December dividend payment on the calendar and a fresh buyback under way, near‑term shareholder returns continue to underpin the investment case even as the stock remains sensitive to every twist in the crude market.

Sources: Financial Times market data (price, range, market cap, dividend dates), Reuters (pipeline update; oil market levels and drivers), BP RNS Q3 2025 results presentation (capital returns and guidance).

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
Google Stock Today: Alphabet (GOOGL, GOOG) Soars on AI Boom – 2025 Update & Forecast
Previous Story

Alphabet (GOOGL) Stock Price Today, Nov. 18, 2025: Buffett’s Big Bet, AI Bubble Fears, and What to Watch Before the Bell

Boaz Weinstein’s Saba Sells Credit Default Swaps on Big Tech as AI Debt Fears Surge
Next Story

Boaz Weinstein’s Saba Sells Credit Default Swaps on Big Tech as AI Debt Fears Surge

Go toTop